secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2024-09-25T23:59:59+00:00
Accession:  0001493152-24-038108
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx increases RenovoCath production, expands Medical Murray partnership with warrant for 709,500 shares
--------------------------------------------------------------------------------

- RenovoRx boosts production of FDA-cleared RenovoCath catheter due to strong physician demand; over 500 procedures performed.
- New work order with Medical Murray; RenovoRx issues warrant for up to 709,500 shares to incentivize manufacturing milestones.
- Phase III TIGeR-PaC trial in pancreatic cancer continues; 52nd event (interim analysis) expected late 2024 or early 2025.
- CEO expects commercial launch of RenovoCath as standalone device to generate revenue during 2025; sufficient cash on hand.
- Robert Strasser promoted to VP of R&D and Operations to lead manufacturing and commercial strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315224038108/0001493152-24-038108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315224038108/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-038108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer